Glen has led QSP modeling projects involving gene therapy to treat diseases including Huntington’s disease, Hemophilia, Hereditary Angio Edema (HAE) and Friedreich’s Ataxia (FA). Glen’s recent work has focused on modeling of drug distribution in CNS tissues via different routes of administration including intraparenchymal and intra-CSF injections.

Glen founded RES Group in 2001. He is a graduate of Massachusetts Institute of Technology (Ph.D.) and University of British Columbia (B.A.Sc.) in Chemical Engineering.

John has led QSP modeling projects involving immuno-oncology/oncology, inflammation & immunology, and oncolytic viruses, at all stages of drug development, from early preclinical through clinical trials. Most recently, John has led the development of disease/therapeutic models for the treatment of Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Non-Small Cell Lung Cancer (NSCLC), Non-Hodgkin’s Lymphoma (NHL), Niemann-Pick Disease and Hepatitis C Virus (HCV).

John joined RES in 2003. Prior to joining RES, John was lead developer for the ABACUSS and DAEPACK computational tool projects at MIT. He received a Ph.D. from the Massachusetts Institute of Technology and a B.S. from California State Polytechnic University, both in Chemical Engineering.

Taeshin has led QSP modeling projects involving neurodegenerative diseases, oncology, inflammation & immunology, rare diseases, and drug dissolution. Most recently, Taeshin has led the development of disease/therapeutic models for the treatment of Alzheimer’s Disease, Parkinson’s Disease, Fabry Disease, Gastric Cancers, Rheumatoid Arthritis (RA), Osteoarthritis (OA), Atopic Dermatitis, and Acute Myeloid Leukemia (AML).

Taeshin joined RES in 2002. While at RES, Taeshin has received several research grant awards from NIH and NSF to advance QSP modeling technologies. He received his Ph.D. from the Massachusetts Institute of Technology, and his M.S. and B.S. degrees from Seoul National University, both in Chemical Engineering.

Zhiwei has led QSP modeling projects involving inflammation & immunology, immunogenicity, rare diseases, gene therapy and PBPK for monoclonal antibodies. Most recently, Zhiwei has led the development of disease/therapeutic models for the treatment of Narcolepsy, Mastitis, Hereditary Angioedema (HAE), Hemophilia, Huntington’s Disease and Sick Cell Disease.

Zhiwei joined RES in 2003. He received his Ph.D. from Colorado School of Mines and B.S. from Tsinghua University, both in Chemical Engineering.

Paul joined RES in 2008. He received his Ph.D. in Molecular Immunology from Loyola University Chicago, and began working in QSP during his postdoctoral studies at Massachusetts Institute of Technology, and Harvard Medical School.

Paul has led QSP modeling projects in oncology, inflammation & immunology, neurology, and lysosomal disorder diseases. Most recently, Paul has led the development of disease/therapeutic models for the treatment of Multiple Myeloma, Acute Myeloid Leukemia (AML), Pancreatic Cancer, Gaucher, Fabry, Duchenne Muscular Dystrophy (DMD).

Haobin has led QSP modeling projects involving rare diseases, inflammation & immunology and PBPK for monoclonal antibodies.  Most recently, Haobin has led the development of disease/therapeutic models for the treatment of Hereditary Angioedema (HAE), Asthma, Idiopathic Pulmonary Fibrosis (IPF), Warm Autoimmune Hemolytic Anemia (WAIHA), Short Bowel Syndrome (SBS) and Hepatitis C Virus (HCV).

Haobin joined RES in 2005.  He received his Ph.D. from the Stony Brook University, and his M.S. and B.S. degrees from Jilin University, both in Materials Science and Engineering.

Kate has led QSP modeling projects in a wide range of disease/therapeutic areas ADC (Antibody Drug Conjugate) for treatment of Gastric Cancers, Circadian Rhythm for Parkinson’s Disease treatment, Hematologic cancers and arthritis treatments including OA (Osteoarthritis) and RA (Rheumatoid Arthritis). 

Kate joined RES in 2010.  She received her Ph.D., M.S. and B.S. degrees from the Korea Advanced Institute of Science and Technology (KAIST), all in Chemical Engineering.